Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2020

Open Access 01-12-2020 | Lymphoma | Research

Analysis of the response time to involved-field radiotherapy in primary gastrointestinal low-grade B-cell lymphoma

Authors: Kyu Hye Choi, Han Hee Lee, Seung-Eun Jung, Kyung-Sin Park, Joo-Hyun O, Young-Woo Jeon, Byung-Ock Choi, Seok-Goo Cho

Published in: Radiation Oncology | Issue 1/2020

Login to get access

Abstract

Background

Early-stage primary gastrointestinal (GI) low-grade B-cell lymphoma shows good therapeutic response to primary radiotherapy. However, there is no clear guideline for the evaluation of response to radiation therapy currently. The aim of this study was to analyze the relationship between the best response time and the clinical course after radiotherapy.

Methods

Patients who underwent radiotherapy for treatment of primary GI low-grade B-cell lymphoma from September 2007 to December 2018 at Seoul St. Mary’s Hospital were included. Early responders were defined by best response within 6 months after radiotherapy, and delayed responders after 6 months. Clinical and pathological factors associated with delayed response and survival analyses were performed to investigate the recurrence and survival during follow-up.

Results

A total of 43 patients were evaluated and the number of gastric mucosa-associated lymphoid tissue and duodenal follicular lymphoma was 36 and 7, respectively. All of 43 patients showed complete remission to radiotherapy and the best response time after radiotherapy was a median of 3 months. There were 8 delayed responders with a median duration of 8.9 months. Early and delayed responders were characterized by a significant difference in depth of invasion beyond the mucosal layer.

Conclusions

Delayed responders did not show differences in oncological outcomes compared with early responders. They were allowed to watch and wait for an additional 6 to 12 months without further treatment.
Literature
1.
Nakamura S, Matsumoto T. Gastrointestinal lymphoma: recent advances in diagnosis and treatment. Digestion. 2013;87:182–8.CrossRef
2.
Nakamura S, Matsumoto T, Iida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: a clinicopathologic analysis of 455 patients with special reference to its time trends. Cancer. 2003;97:2462–73.CrossRef
3.
Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697–707.CrossRef
4.
Juarez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary gastric lymphoma, epidemiology, clinical diagnosis, and treatment. Cancer Control. 2018;25:1073274818778256.CrossRef
5.
Gong EJ, Ahn JY, Jung HY, Park H, Ko YB, Na HK, Jung KW, Kim Do H, Lee JH, Choi KD, Song HJ, Lee GH, Kim JH. Helicobacter pylori eradication therapy is effective as the initial treatment for patients with H. pylori-negative and disseminated gastric mucosa-associated lymphoid tissue lymphoma. Gut Liver. 2016;10:706–13.CrossRef
6.
Stathis A, Chini C, Bertoni F, Proserpio I, Capella C, Mazzucchelli L, Pedrinis E, Cavalli F, Pinotti G, Zucca E. Long-term outcome following helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. J Ann Oncol. 2009;20:1086–93.CrossRef
7.
Pinotti G, Zucca E, Roggero E, Pascarella A, Bertoni F, Savio A, Savio E, Capella C, Pedrinis E, Saletti P, Morandi E, Santandrea G, Cavalli F. Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. Leuk Lymphoma. 1997;26:527–37.CrossRef
8.
Aleman BM, Haas RL, van der Maazen RW. Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. J Best Pract Res Clin Gastroenterol. 2010;24:27–34.CrossRef
9.
Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A. Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92:11–31.CrossRef
10.
Mac Manus MP, Hoppe RT. Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. J Clin Oncol. 1996;14:1282–90.CrossRef
11.
Brady JL, Binkley MS, Hajj C, Chelius M, Chau K, Balogh A, Levis M, Filippi AR, Jones M, Mac Manus M, Wirth A, Oguchi M, Vistisen AK, Andraos TY, Ng AK, Aleman BMP, Choi SH, Kirova Y, Hardy S, Reinartz G, Eich HT, Bratman SV, Constine LS, Suh CO, Dabaja B, El-Galaly TC, Hodgson DC, Ricardi U, Yahalom J, Hoppe RT, et al. Definitive radiotherapy for localized follicular lymphoma staged by (18)F-FDG PET-CT: a collaborative study by ILROG. Blood. 2019;133:237–45.CrossRef
12.
Haas RL, Poortmans P, de Jong D, Aleman BM, Dewit LG, Verheij M, Hart AA, van Oers MH, van der Hulst M, Baars JW, Bartelink H. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474–80.CrossRef
13.
Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, Grothaus-Pinke B, Reinartz G, Brockmann J. Temmesfeld A: Primary gastrointestinal non-Hodgkin’s lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma—results of the prospective German multicenter study GIT NHL 01/92. J Clin Oncol. 2001;19:3874–83.CrossRef
14.
Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. J Hematol oncol. 2005;23:10–7.CrossRef
15.
Vrieling C, de Jong D, Boot H, de Boer JP, Wegman F, Aleman BM. Long-term results of stomach-conserving therapy in gastric MALT lymphoma. J Radiotherapy. 2008;87:405–11.CrossRef
16.
Goda JS, Gospodarowicz M, Pintilie M, Wells W, Hodgson DC, Sun A, Crump M, Tsang RW. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. J Cancer. 2010;116:3815–24.CrossRef
17.
Kim S-W, YCA DHL, Kim WS, Kim SJ, Ko YH, Kim K-M. Clinical outcomes of radiation therapy for early-stage gastric mucosa-associated lymphoid tissue lymphoma. J World J Gastroenterol. 2013;19:6062.CrossRef
18.
Elsayad K, Reinartz G, Oertel M, Rehn S, Eismann J, Scobioala S, Berssenbrügge H, Eter N, Weishaupt C, Schmidt HH, Friedrichs B, Grünewald I, Hartmann W, Lenz G, Wardelmann E, Willich N, Eich HT. Radiotherapy of extranodal low-grade follicular and marginal zone lymphomas: long-term follow-up of 159 patients. Strahlenther Onkol. 2020;196:117–25.CrossRef
19.
Lowry L, Smith P, Qian W, Falk S, Benstead K, Illidge T, Linch D, Robinson M, Jack A, Hoskin P. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial. Radiother Oncol. 2011;100:86–92.CrossRef
20.
Lee H, Oh D, Yang K, Ko YH, Ahn YC, Kim WS, Kim SJ. Radiation therapy outcome and clinical features of duodenal-type follicular lymphoma. Cancer Res Treat. 2019;51:547–55.CrossRef
21.
Ruskone-Fourmestraux A, Lavergne A, Aegerter P, Megraud F, Palazzo L, De Mascarel A, Molina T, Rambaud JL. Predictive factors for regression of gastric MALT lymphoma after anti-helicobacter pyloritreatment. Gut. 2001;48:297–303.CrossRef
22.
Hussell T, Isaacson PG, Crabtree JE, Spencer J. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to helicobacter pylori. Lancet. 1993;342:571–4.CrossRef
23.
Savio A, Zamboni G, Capelli P, Negrini R, Santandrea G, Scarpa A, Fuini A, Pasini F, Ambrosetti A, Paterlini A, Buffoli F, Angelini GP, Cesari P, Rolfi F, Graffeo M, Pascarella A, Valli M, Mombello A, Ederle A, Franzin G. Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial in the north-east of Italy and evaluation of the diagnostic protocol's adequacy. Recent Results Cancer Res. 2000;156:116–24.CrossRef
24.
Vetro C, Romano A, Chiarenza A, Conticello C, Donnarumma D, Gorgone A, Coppolino F, Palumbo GA, Bonanno G, Di Raimondo F. Endoscopic ultrasonography in gastric lymphomas: appraisal on reliability in long-term follow-up. Hematol Oncol. 2012;30:180–5.CrossRef
25.
El-Zahabi LM, Jamali FR, El H II, Naja M, Salem Z, Shamseddine A, El-Saghir NS, Zaatari G, Geara F, Soweid AM. The value of EUS in predicting the response of gastric mucosa-associated lymphoid tissue lymphoma to helicobacter pylori eradication. Gastrointest Endosc. 2007;65:89–96.CrossRef
26.
Steinbach G, Ford R, Glober G, Sample D, Hagemeister FB, Lynch PM, McLaughlin PW, Rodriguez MA, Romaguera JE, Sarris AH, Younes A, Luthra R, Manning JT, Johnson CM, Lahoti S, Shen Y, Lee JE, Winn RJ, Genta RM, Graham DY, Cabanillas FF. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med. 1999;131:88–95.CrossRef
27.
Nakamura S, Matsumoto T, Suekane H, Takeshita M, Hizawa K, Kawasaki M, Yao T, Tsuneyoshi M, Iida M, Fujishima M. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of helicobacter pylori. Gut. 2001;48:454–60.CrossRef
28.
Ruskoné-Fourmestraux A, Fischbach W, Aleman BMP, Boot H, Du MQ, Megraud F, Montalban C, Raderer M, Savio A, Wotherspoon A. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60:747–58.CrossRef
29.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA, Alliance AL, Lymphoma G, Eastern Cooperative Oncology G, European Mantle Cell Lymphoma C, Italian Lymphoma F, European Organisation for R, Treatment of Cancer/Dutch Hemato-Oncology G, Grupo Español de Médula Ó, German High-Grade Lymphoma Study G, German Hodgkin's Study G, Japanese Lymphorra Study G, Lymphoma Study A, Group NCT, Nordic Lymphoma Study G, Southwest Oncology G, United Kingdom National Cancer Research I: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014, 32:3059–3068.
30.
Zullo A, Hassan C, Andriani A, Cristofari F, Cardinale V, Spinelli GP, Tomao S, Morini S. Primary low-grade and high-grade gastric MALT-lymphoma presentation. J Clin Gastroenterol. 2010;44:340–4.CrossRef
Metadata
Title
Analysis of the response time to involved-field radiotherapy in primary gastrointestinal low-grade B-cell lymphoma
Authors
Kyu Hye Choi
Han Hee Lee
Seung-Eun Jung
Kyung-Sin Park
Joo-Hyun O
Young-Woo Jeon
Byung-Ock Choi
Seok-Goo Cho
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2020
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-020-01649-6

Other articles of this Issue 1/2020

Radiation Oncology 1/2020 Go to the issue

Letter to the Editor

In regard to Cuccia et al.: impact of hydrogel peri-rectal spacer insertion on prostate gland intra-fraction motion during 1.5 T MR-guided stereotactic body radiotherapy

Research

Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma

Commentary

PITChing (professional organisations, innovative trial designs and collaborative approach) for evidence generation for proton therapy

Research

Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer

Research

Hypofractionated intensity-modulated radiotherapy with concurrent chemotherapy for elderly patients with locally advanced pancreatic carcinoma

Research

Radiotherapy alone for stage IE ocular adnexal mucosa-associated lymphoid tissue lymphomas: long-term results